Inhaled drug delivery is ideal for systemic and local delivery. It speeds up therapy onset and reduces dosing. Making inhaled therapies is complex and perceived as difficult. In this webinar we will show you how Soft Mist Inhalers (SMI) can simplify and de-risk inhaled product development programmes. This webinar will be an in-depth analysis of SMI technology to harness its potential: design, performance, use and benefits in the development of Inhaled dosage forms.
The questions we will address are:
• How to formulate SMIs
• How to test SMIs
• How to launch SMIs
The webinar will take MRX004 SMI as an example and review what it offers: a simplified and de-risked device platform, versatile enough to be used with soluble and insoluble APIs. Kindeva and Merxin have worked together to generate performance data that will showcase SMI and MRX004 opportunities. Merxin makes the device, Kindeva develops the formulations and executes the performance testing.
The webinar will focus on “how-to” tips: starting with the design of the device to its use in in-vivo situations. We will look at the different aspects of SMI technology that are instrumental in the success of the development of new inhaled therapies. We will explain how MRX004 functions and how it is integrated in development programs to accelerate development pathways from the clinic to commercial launch. Details on the design, performance and testing of MRX004 will be shared. MRX004 is a portable and active device designed for drug delivery to the deep lungs. It can deliver a large number of doses, and we will show how it has been used to deliver up 1 mg of active in one dose. MRX004 is also a green inhaler with a low carbon footprint, similar to DPIs.
The webinar will demonstrate our capability to formulate your molecule and then to develop and optimise the performance testing in these complex devices. We will present the evaluations already completed with formulations in MRX004. Working together we can ensure the successful evaluation of your molecule in an SMI, navigating the various global regulatory challenges, to enable the realisation of your molecule’s full potential.
In particular, we will look at:
• Device design
• Formulating options
• Performance testing
• What can and cannot be achieved with SMIs
• Regulatory requirements
• Lifecycle management of existing therapies
• Integrating SMI in a product development plan
By the end of the webinar you will know how to assess your portfolio against the SMI potential and you will have the starting point to make an SMI. The aim of the webinar is to give you the confidence that you can initiate an SMI project without compromising on speed to market or quality knowing that you can rely on unparalleled support and expertise from the Kindeva and Merxin teams.
The synergy of Merxin and Kindeva, that brings together a track record of exceptionally successful device and product expertise, will meet your product development needs and will help you launch your next product.
Register for this webinar to increase the value of your product portfolio, gear up your inhalation drug delivery projects to create inhalation therapies that will leave your competitors in the starting blocks.
Let us introduce you to SMIs: register now, places are limited.
